2016
SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer
Nahleh ZA, Barlow WE, Hayes DF, Schott AF, Gralow JR, Sikov WM, Perez EA, Chennuru S, Mirshahidi HR, Corso SW, Lew DL, Pusztai L, Livingston RB, Hortobagyi GN. SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer. Breast Cancer Research And Treatment 2016, 158: 485-495. PMID: 27393622, PMCID: PMC4963434, DOI: 10.1007/s10549-016-3889-6.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerEvent-free survivalAddition of bevacizumabInflammatory breast cancerAdvanced breast cancerDose-dense doxorubicinNab-paclitaxelPathologic complete responseBreast cancerPCR rateOverall survivalOpen-label phase II clinical trialHormone receptor-positive diseaseImproved event-free survivalPathologic complete response ratePhase II clinical trialNeoadjuvant chemotherapy armNeoadjuvant nab-paclitaxelRole of bevacizumabWeekly nab-paclitaxelComplete response rateReceptor-positive diseaseHormone receptor statusSequence of administrationChemotherapy arm
2013
TIG1 Promotes the Development and Progression of Inflammatory Breast Cancer through Activation of Axl Kinase
Wang X, Saso H, Iwamoto T, Xia W, Gong Y, Pusztai L, Woodward WA, Reuben JM, Warner SL, Bearss DJ, Hortobagyi GN, Hung MC, Ueno NT. TIG1 Promotes the Development and Progression of Inflammatory Breast Cancer through Activation of Axl Kinase. Cancer Research 2013, 73: 6516-6525. PMID: 24014597, PMCID: PMC6135947, DOI: 10.1158/0008-5472.can-13-0967.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsApoptosisAxl Receptor Tyrosine KinaseBlotting, WesternCell AdhesionCell CycleCell MovementCell ProliferationDisease ProgressionFemaleFluorescent Antibody TechniqueHumansImmunoprecipitationInflammatory Breast NeoplasmsMediator ComplexMiceNeoplasm InvasivenessProto-Oncogene ProteinsReal-Time Polymerase Chain ReactionReceptor Protein-Tyrosine KinasesReverse Transcriptase Polymerase Chain ReactionRNA, MessengerRNA, Small InterferingSignal TransductionTumor Cells, CulturedConceptsInflammatory breast cancerBreast cancerAxl expressionMalignant propertiesHigh tumoral expressionIBC cell proliferationMatrix metalloproteinase-9Inhibited tumor growthIBC specimensIBC cellsShorter survivalTumoral expressionProteasome-dependent degradationMetalloproteinase-9TIG1 expressionNF-κBTherapeutic targetTumor growthReceptor tyrosine kinasesAxl functionLethal formAxlIBC treatmentCancerAggressive propertiesComparison of molecular subtype distribution in triple-negative inflammatory and non-inflammatory breast cancers
Masuda H, Baggerly KA, Wang Y, Iwamoto T, Brewer T, Pusztai L, Kai K, Kogawa T, Finetti P, Birnbaum D, Dirix L, Woodward WA, Reuben JM, Krishnamurthy S, Symmans W, Van Laere SJ, Bertucci F, Hortobagyi GN, Ueno NT. Comparison of molecular subtype distribution in triple-negative inflammatory and non-inflammatory breast cancers. Breast Cancer Research 2013, 15: r112. PMID: 24274653, PMCID: PMC3978878, DOI: 10.1186/bcr3579.Peer-Reviewed Original ResearchConceptsInflammatory breast cancerTriple-negative breast cancerTN-IBCIBC statusTNBC subtypesBreast cancerTNBC cohortClinical outcomesNon-inflammatory breast cancerMolecular subtype distributionWorld IBC ConsortiumRecurrence-free survivalNon-inflammatory typeClinical characteristicsOverall survivalPoor prognosisClinical behaviorSubtype distributionConclusionsOur dataHeterogeneous diseaseSubtypesCancerSignificant predictorsGene expression profilesCohort
2011
Recommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast Cancer
Kaufmann M, von Minckwitz G, Mamounas EP, Cameron D, Carey LA, Cristofanilli M, Denkert C, Eiermann W, Gnant M, Harris JR, Karn T, Liedtke C, Mauri D, Rouzier R, Ruckhaeberle E, Semiglazov V, Symmans WF, Tutt A, Pusztai L. Recommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast Cancer. Annals Of Surgical Oncology 2011, 19: 1508-1516. PMID: 22193884, DOI: 10.1245/s10434-011-2108-2.Peer-Reviewed Original ResearchConceptsNeoadjuvant systemic therapyPrimary breast cancerBreast cancerSystemic therapyBreast-conserving surgery rateLarge adjuvant trialsPathologic complete responseInflammatory breast cancerNew therapeutic regimensIntermediate end pointsInternational Consensus ConferenceClinical research groupAdjuvant trialsNew regimensPathologic responseComplete responseSurgery ratesTherapeutic regimensConsensus conferenceEnd pointTherapyCancerTrialsRegimensPanel of representativesP2-02-01: A Novel Inflammatory Breast Cancer-Specific Oncogene, Tazarotene-Induced Gene 1, Promotes Tumorigenicity and Invasiveness through the Receptor Tyrosine Kinase Axl.
Wang X, Saso H, Iwamoto T, Pusztai L, Gong Y, Woodward W, Reuben J, Hortobagyi G, Ueno N. P2-02-01: A Novel Inflammatory Breast Cancer-Specific Oncogene, Tazarotene-Induced Gene 1, Promotes Tumorigenicity and Invasiveness through the Receptor Tyrosine Kinase Axl. Cancer Research 2011, 71: p2-02-01-p2-02-01. DOI: 10.1158/0008-5472.sabcs11-p2-02-01.Peer-Reviewed Original ResearchInflammatory breast cancerReceptor tyrosine kinase AXLTIG1 expressionTyrosine kinase AXLBreast cancerSUM149 cellsTumor growthEffective standard therapyNon-IBC cell linesPrognosis of patientsTreatment of patientsMammary fat padMatrix metalloproteinase-9Athymic nude miceIBC cell linesCell linesIBC cellsStandard therapyGene 1 expressionMolecular mechanismsDownregulation of expressionAxl expressionClinical subtypesMetalloproteinase-9Malignant process
2010
Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer
Iwamoto T, Bianchini G, Qi Y, Cristofanilli M, Lucci A, Woodward WA, Reuben JM, Matsuoka J, Gong Y, Krishnamurthy S, Valero V, Hortobagyi GN, Robertson F, Symmans WF, Pusztai L, Ueno NT. Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer. Breast Cancer Research And Treatment 2010, 125: 785-795. PMID: 21153052, PMCID: PMC4109066, DOI: 10.1007/s10549-010-1280-6.Peer-Reviewed Original ResearchConceptsInflammatory breast cancerClinical subtypesBreast cancerNon-IBC patientsCase-control studyDistinct clinical subtypesDifferent molecular subtypesNon-IBC tumorsSignificant differencesNon-IBC specimensImmune system-related pathwaysLipid metabolism-related pathwaysHER2 statusReceptor phenotypeMetabolism-related pathwaysMolecular subtypesIBC tumorsSurvival curvesSubtypesTumor samplesHormone receptorsCancerPatientsT-testHER2
2009
Epstein-Barr virus (EBV) in fine needle aspirates containing inflammatory breast cancer cells.
Li C, Pusztai L, Cohen E, Symmans F, Wang B, Lee B, Hortobagyi G, Cristofanilli M, Reuben J. Epstein-Barr virus (EBV) in fine needle aspirates containing inflammatory breast cancer cells. Cancer Research 2009, 69: 3084. DOI: 10.1158/0008-5472.sabcs-3084.Peer-Reviewed Original ResearchInflammatory breast cancerEpstein-Barr virusFine needle aspiratesEBV DNABreast cancerEBV genomeQuantitative polymerase chain reactionLABC patientsNeedle aspiratesFNA samplesHuman herpes virus 8Findings warrants further investigationPotential viral oncogenesAdvanced breast cancerLatent EBV infectionHerpes virus 8Primary breast cancerBreast cancer patientsPossible viral etiologyEBV DNA sequencesQ-PCRInflammatory breast cancer cellsMouse mammary tumorsBreast cancer cellsWarrants further investigation